Which type of drug-resistant patients does brigatinib show efficacy for?

Brigatinib is a new anti-cancer drug that has shown significant efficacy in targeting specific types of drug-resistant patients.

Brigatinib has significant efficacy in drug-resistant patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Such patients usually develop drug resistance after treatment with other ALK inhibitors (such as crizotinib, ceritinib, etc.). As a next-generation ALK-TKI drug, brigatinib has a wider range of targets and can effectively inhibit multiple drug-resistant point mutations.

Clinical studies have shown that brigatinib has shown certain efficacy in the treatment of patients with alectinib resistance. For example, data from a certain II phase clinical study showed that the overall response rate (ORR) of patients in the main study cohort reached 34%, and the disease control rate ( pan>DCR) was 79%, and the median progression-free survival (PFS) was 7.3 months. These data show that brigatinib can effectively control the disease progression of patients with ALKpositive advanced NSCLC resistance and improve the quality of life of patients.

In addition to ALKpositive late stage NSCLC resistant patients, brigatinib also has a significant effect on osimertinib resistance in EGFR mutated non-small cell lung cancer (NSCLC). Osimertinib is an important therapeutic drug for patients with EGFR mutationsNSCLC. However, as treatment progresses, some patients will develop drug resistance.

Brigatinib can effectively overcome osimertinib resistance by combining with other drugs (such as cetuximab). For example, for T790M/C797Scis mutation is a common resistance mechanism to osimertinib, and the treatment regimen of brigatinib combined with cetuximab has achieved significant clinical results. A study shows that the effective rate of patients using this combination treatment reaches 60%, which is significantly better than traditional chemotherapy and delays the time of drug resistance.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC9669367/